Ala Ali 已转推
Dapagliflozin is not dialyzable and does not accumulate significantly in dialysis patients—supporting biological plausibility for safe use.
CME INDIA Clinical Pearls: SGLT2 Inhibitors in Dialysis (HD & PD)
▪️Evidence Gap Alert:
While SGLT2 inhibitors robustly reduce CKD progression, CV events, and mortality in non-dialysis CKD, patients on dialysis (HD/PD) were excluded from all landmark RCTs, creating a major evidence void.
▪️Mechanistic Shift in ESKD:
In dialysis patients, classical glucosuric/tubular effects are minimal due to low nephron mass; benefits are likely mediated via cardio-metabolic off-target pathways (↓ inflammation, ↓ oxidative stress, improved myocardial energetics).
▪️Pharmacokinetic Reassurance: Dapagliflozin is not dialyzable and does not accumulate significantly in dialysis patients—supporting biological plausibility for safe use.
▪️Signal from Early Data:
Small trials and observational cohorts suggest potential CV benefit, improved volume status, and preservation of residual kidney function, particularly in incremental dialysis—without major safety signals.
▪️Peritoneal Dialysis Uncertainty:
In PD, evidence is sparse and inconsistent—some studies show ↑ ultrafiltration and ↓ BP, while others show no effect on peritoneal glucose transport.
▪️Real-World Cohort Insight:
Retrospective analyses indicate lower CV events and mortality in dialysis patients using SGLT2i, but these are hypothesis-generating, not definitive.
▪️Safety Perspective:
No major red flags so far, but risk of volume depletion, hypotension, and rare euglycemic ketoacidosis warrants cautious patient selection.
▪️Clinical Position Today:
Routine use in dialysis cannot be recommended yet; use should be individualized and preferably within research settings or expert supervision.
▪️Future Direction:
Ongoing large RCTs are critical to define efficacy, safety, and patient selection—this could expand SGLT2i use into ESKD therapeutics beyond glycemia.
💢Take-Home Message:
👉 SGLT2 inhibitors in dialysis represent a promising but unproven frontier—mechanistically attractive, observationally encouraging, but awaiting definitive trial evidence before mainstream adoption.
academic.oup.com/ckj/article/19…
English
